Advancing Bispecific and Combination Therapy to the Clinic focuses on novel concepts and their developments. Presentations will include synergistic combinations together with their rationale and provide data showing improved performance, including potency, targeting, stability, half-life and reduced toxicity. Preclinical studies leading up to proof-of-concept and IND enabling studies will be included as well as developments up to phases 2 and 3 for the more advanced products.
NEW APPROACHES TO DEVELOPMENT
KEYNOTE PRESENTATION: Bispecific Antibody; Discovery, Development and Next Generation
Tomoyuki Igawa, PhD, CEO, Head, Research, Global Biologics Leader, Chugai Pharmabody Research Pte. Ltd.
Engineering and Development of a T Cell Bispecific for Colorectal Cancer
Adam Root, PhD, Senior Principal Scientist, Global Biotherapeutics, Pfizer, Inc.
Targeting Cancer with BiTE® Antibody Constructs
Roman Kischel, MD, Director, Research, Amgen Research (Munich) GmbH
BISPECIFICS FOR T-CELL ENGAGEMENT DEMONSTRATING SUPERIOR PROPERTIES
Progress with Bispecific Vγ9Vδ2-T Cell Engagers
Paul W.H.I. Parren, PhD, Executive Vice President, Head, R&D Lava Therapeutics B.V.
Preclinical Combinations of T Cell Bispecifics Targeting Solid Tumors and Hematological Malignancies
Marina Bacac, PhD, Head, Cancer Immunotherapy Department 2 (CIT-2), Roche Innovation Center Zurich
A Novel Mucin 16 Bispecific T Cell Engaging Antibody for the Treatment of Ovarian Cancer
Alison Crawford, PhD, Senior Staff Scientist, Oncology and Angiogenesis, Regeneron Pharmaceuticals, Inc.
The Journey to 'the' Antibody: Tailoring for Success
María González Pajuelo, CSO, FairJourney Biologics
OVERCOMING PROBLEMS ARISING IN THE CLINIC / CYTOKINE RELEASE ASSAYS
Problems that Arise in the Clinic Regarding TME, Immuno-Suppression and T Cell Exhaustion
Tariq Ghayur, PhD, Distinguished Research Fellow, Abbvie Bioresearch
An International Collaborative Study to Establish a 1st Reference Panel for Cytokine Release Assays
Sandrine Vessillier, PhD, Principal Scientist, Head, Immunotoxicology Cellular Immunology, Biotherapeutics, National Institute for Biological Standards and Control, UK
INNOVATIVE PLATFORMS YIELDING PRODUCTS HEADING FOR THE CLINIC
DuoHexaBody-CD37, a Novel CD37-Targeting Bispecific Antibody with a Hexamerization-Enhancing Mutation, Demonstrating Superior Preclinical Activity Against Malignant B Cells in vitro, ex vivo and in vivo
Laurens Kil, PhD, Senior Scientist, Genmab B.V.
Towards RNA-Based Cancer Immunotherapy: Advances in the Development of mRNA Encoded Therapeutic Antibodies
Ursula Ellinghaus, PhD, Scientist, Bispecific Antibodies, BioNTech RNA Pharmaceuticals GmbH
Anticalin Proteins and their Application in Respiratory Disease
Christine Rothe, PhD, VP, Discovery & Alliance Management, Pieris Pharmaceuticals GmbH
BISPECIFICS FOR CHECKPOINT INHIBITORS TOGETHER WITH ANTAGONISTS OR AGONISTS
Design Meets Biology – Engineering a PD-1/CTLA-4 Bispecific Antibody to Improve Both Safety and Efficacy
Yariv Mazor, PhD, Senior Scientist, Antibody Discovery & Protein Engineering, MedImmune, LLC
PD-1 x LAG-3 (MGD013) and PD-1 x CTLA-4 (MGD019): Two Clinical-Stage DART® Molecules Designed to Simultaneously Block Two Checkpoint Pathways
Alexey Berezhnoy, PhD, Scientist, Cell Biology & Immunology, MacroGenics, Inc.
A Novel, Monovalent Tri-Specific Antibody-Based Molecule that Simultaneously Modulates PD-L1 and 4-1BB Exhibits Potent Anti-Tumoral Activity in vivo
Sebastian Meyer, PhD, COO, Numab Innovation AG
SCREENING AND IDENTIFICATION OF BISPECIFIC AND NON-BISPECIFIC COMBINATIONS
Unbiased Functional Screening of Large Bispecific Antibody Panels to Unlock Novel Biology
Pieter Fokko van Loo, PhD, Director, Oncology-Immunology, Merus N.V.
Benefits of Chicken-Derived Antibodies for Combination Immunotherapy
Klaus Koefoed, PhD, MSc, Director, Antibody Technology, Symphogen A/S
* The program is subject to change without notice, due to unforeseen reason.